Skip to main content
. 2012 Aug 1;7(8):e42386. doi: 10.1371/journal.pone.0042386

Figure 5. Role of TAK1 and p38 MAPK on NOD1 and TLR4 ligand mediated CXCL8 release by HMVEC.

Figure 5

CXCL8 release at 24 hours in HMVEC stimulated by iE-DAP 10 µg/ml (NOD1 agonist) or LPS 1 µg/ml (TLR4 agonist) following 30 minutes pre-treatment with (A) the TAK1 inhibitor 5Z-7-oxozeaenol and (B) the p38 mitogen activated protein kinase (p38 MAPK) inhibitor BIRB0796. Results are expressed as a percentage of response to the agonist alone (mean ± SEM; n = 4). Results were analysed by 1-sample t-test (*P<0.05) and by 2-way ANOVA (#P<0.05 vs. LPS).